CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted
Drug / intervention
Risperidonedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00395499
NCT00395499N/ACompleted
CompareCT.gov

Measurement of Risperidone and 9-Hydroxyrisperidone in Plasma and Saliva

Ohio State University·observational·Posted Nov 3, 2006·Updated Jun 23, 2016

In Brief

An observational study evaluating Risperidone for Patients Already Taking Risperidone for Clinical Indications. Completed, across 2 sites.

Detailed Summary

The purpose of this research is to: (1) examine the secrection of risperidone (RIS) (Risperdal) and its metabolite, 9-OH-RIS, in saliva, (2) determine the concentration ratio of RIS and 9-OH-RIS between plasma and saliva, and (3) compare the rate of decline in concentration of RIS and 9-OH-RIS in saliva and plasma by measurements at timed intervals during a single dosing interval.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPatients Already Taking Risperidone for Clinical Indications
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)

Timeline

N/ACompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 3, 2006
Enrollment StartMay 1, 2001
Study CompletionApr 1, 2003
TodayJul 2, 2026
Posted 19.7 years ago

Interventions

Risperidonedrug